USClinicalTrials.gov【Trial record】
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Phase 1/2RecruitingSource updated: Oct 1, 2026
Cancer types
Breast Cancer
All subtypes, incl. HR+, HER2+, TNBC. 92 official records currently indexed across three regions.
Trial records retrieved live from the ClinicalTrials.gov public API.
Showing 92 of 92
Highlight terms:
Build a discussion list0 selected
Select the public official records you want to take to your appointment, then generate a list. Nothing is ranked or recommended — the list only reproduces titles and links.
Not signed in — up to 5 records per list. Sign in for higher free limits, or see Pro for more exports.
USEUClinicalTrials.gov【Trial record】
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Phase 2RecruitingSource updated: Oct 1, 2026
USEUClinicalTrials.gov【Trial record】
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Phase 2RecruitingSource updated: Oct 1, 2026
USEUCNOTHERClinicalTrials.gov【Trial record】
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2RecruitingSource updated: Oct 1, 2026
USEUCNOTHERClinicalTrials.gov【Trial record】
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Phase 1/2RecruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Phase 1RecruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
Phase 2RecruitingSource updated: Oct 1, 2026
USOTHERClinicalTrials.gov【Trial record】
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Phase 3RecruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
Phase 3Active, not recruitingSource updated: Oct 1, 2026
OTHERClinicalTrials.gov【Trial record】
Cardioprotection Effect of Linagliptin
Phase 3Not yet recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
Not applicableRecruitingSource updated: Oct 1, 2026
USOTHERClinicalTrials.gov【Trial record】
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Phase 3Active, not recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients
Phase 2RecruitingSource updated: Oct 1, 2026
USOTHERClinicalTrials.gov【Trial record】
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Phase 3Active, not recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel
Phase 2Active, not recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Fit2ThriveMB: Optimization of a Physical Activity Promotion Intervention for Metastatic Breast Cancer Patients
Not applicableNot yet recruitingSource updated: Oct 1, 2026
USEUOTHERClinicalTrials.gov【Trial record】
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
Phase 3Active, not recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
Phase 2RecruitingSource updated: Oct 1, 2026
USEUOTHERClinicalTrials.gov【Trial record】
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1RecruitingSource updated: Oct 1, 2026
USEUCNOTHERClinicalTrials.gov【Trial record】
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Phase 3RecruitingSource updated: Oct 1, 2026
EUClinicalTrials.gov【Trial record】
Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study
Not applicableRecruitingSource updated: Oct 1, 2026
USEUCNOTHERClinicalTrials.gov【Trial record】
Roll-over Study to Allow Continued Access to Ribociclib
Phase 4Active, not recruitingSource updated: Oct 1, 2026
USEUOTHERClinicalTrials.gov【Trial record】
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 1Active, not recruitingSource updated: Oct 1, 2026
OTHERClinicalTrials.gov【Trial record】
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
Phase 2Active, not recruitingSource updated: Oct 1, 2026
EUClinicalTrials.gov【Trial record】
Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.
Phase 2Active, not recruitingSource updated: Oct 1, 2026
USEUOTHERClinicalTrials.gov【Trial record】
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Phase 3Active, not recruitingSource updated: Oct 1, 2026
USOTHERClinicalTrials.gov【Trial record】
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Phase 2Active, not recruitingSource updated: Oct 1, 2026
USOTHERClinicalTrials.gov【Trial record】
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Phase 2RecruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
Phase 1Not yet recruitingSource updated: Oct 1, 2026
CNClinicalTrials.gov【Trial record】
A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
Phase 3RecruitingSource updated: Sep 30, 2026
USClinicalTrials.gov【Trial record】
Assessing the Time Demands of Cancer
Active, not recruitingSource updated: Sep 30, 2026
CNClinicalTrials.gov【Trial record】
Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer
Phase 2Not yet recruitingSource updated: Sep 30, 2026
EUClinicalTrials.gov【Trial record】
Impact of Sleep Disturbance on Cognition and Quality of Life in Breast Cancer
Not applicableRecruitingSource updated: Sep 30, 2026
USClinicalTrials.gov【Trial record】
Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
Phase 2RecruitingSource updated: Sep 30, 2026
USClinicalTrials.gov【Trial record】
Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning
RecruitingSource updated: Sep 30, 2026
USClinicalTrials.gov【Trial record】
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Phase 1RecruitingSource updated: Sep 30, 2026
USClinicalTrials.gov【Trial record】
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Phase 2RecruitingSource updated: Sep 30, 2026
USClinicalTrials.gov【Trial record】
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Phase 3RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
Not applicableRecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors
Not applicableRecruitingSource updated: Aug 14, 2026
OTHERClinicalTrials.gov【Trial record】
A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer
Phase 2RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Phase 3RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Phase 3RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Phase 1RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Phase 2RecruitingSource updated: Aug 14, 2026
OTHERClinicalTrials.gov【Trial record】
Breast Cancer Plasma Adjuvant Intra-operative Treatment (Breast Cancer PAINT)
Not applicableRecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Not yet recruitingSource updated: Aug 14, 2026
OTHERClinicalTrials.gov【Trial record】
Effectiveness of Video-Based Movement Analysis-Guided Personalized Rehabilitation in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Not applicableEnrolling by invitationSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer
Not applicableActive, not recruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Exercise Oncology Clinic Pilot Feasibility Trial
Not applicableRecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Phase 1/2RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Increasing Breast and Colorectal Cancer Screening in the Community
Not applicableNot yet recruitingSource updated: Aug 14, 2026
CNClinicalTrials.gov【Trial record】
Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
Phase 3RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya
Not applicableRecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Enrolling by invitationSource updated: Aug 14, 2026
CNClinicalTrials.gov【Trial record】
Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
Phase 2RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants
Not applicableNot yet recruitingSource updated: Aug 14, 2026
OTHERClinicalTrials.gov【Trial record】
Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS)
RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia
Not applicableRecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Telehealth Weight Loss Program for Breast Cancer Survivors
Not applicableActive, not recruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Phase 3RecruitingSource updated: Aug 14, 2026
CNClinicalTrials.gov【Trial record】
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer
Phase 2Not yet recruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
'ADVANCE' (A Pilot Trial)
Phase 1Active, not recruitingSource updated: Aug 13, 2026
EUClinicalTrials.gov【Trial record】
Auricular Acupressure for Perioperative Anxiety and Pain in Therapeutic Breast Surgery (ROSA)
Not applicableRecruitingSource updated: Aug 13, 2026
USClinicalTrials.gov【Trial record】
Medical Imaging and Focused Ultrasound Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)
Phase 1RecruitingSource updated: Aug 13, 2026
CNClinicalTrials.gov【Trial record】
Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery
Phase 3RecruitingSource updated: Aug 13, 2026
USClinicalTrials.gov【Trial record】
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Phase 3Active, not recruitingSource updated: Aug 13, 2026
CNClinicalTrials.gov【Trial record】
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）
Phase 2/3Enrolling by invitationSource updated: Aug 13, 2026
USClinicalTrials.gov【Trial record】
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
Phase 2Active, not recruitingSource updated: Aug 13, 2026
CNCDE【Guideline / public regulatory information】
CDE 临床试验默示许可 — clinical trial implied licence notices
Index verified: Aug 16, 2026
CNCDE【Guideline / public regulatory information】
CDE 优先审评公示 — priority review listings
Index verified: Aug 16, 2026
CNCDE【Guideline / public regulatory information】
CDE 受理品种信息 — applications accepted for review
Index verified: Aug 16, 2026
CNCDE【Guideline / public regulatory information】
CDE 指导原则 — published technical guidance documents
Index verified: Aug 16, 2026
CNCDE【Guideline / public regulatory information】
CDE 突破性治疗公示 — breakthrough therapy designation notices
Index verified: Aug 16, 2026
CNCDE【Guideline / public regulatory information】
CDE 附条件批准品种 — conditionally approved products list
Index verified: Aug 16, 2026
CNChiCTR【Guideline / public regulatory information】
ChiCTR — Chinese Clinical Trial Registry, public search
Index verified: Aug 16, 2026
EUCTIS【Guideline / public regulatory information】
CTIS public register — search clinical trials authorised in the EU/EEA
Index verified: Aug 16, 2026
EUEMA【Guideline / public regulatory information】
EMA — CHMP meeting highlights and opinions on new medicines
Index verified: Aug 16, 2026
EUEMA【Guideline / public regulatory information】
EMA — medicines for human use currently under evaluation (monthly CHMP list)
Index verified: Aug 16, 2026
EUEMA【Guideline / public regulatory information】
EMA — searchable database of authorised medicines in the EU
Index verified: Aug 16, 2026
EUESMO【Guideline / public regulatory information】
ESMO Clinical Practice Guidelines — breast cancer
Index verified: Aug 16, 2026
EUESMO【Guideline / public regulatory information】
ESMO Clinical Practice Guidelines — public index by tumour type
Index verified: Aug 16, 2026
EUESMO【Guideline / public regulatory information】
ESMO Clinical Practice Guidelines — supportive and palliative care section
Index verified: Aug 16, 2026
USFDA【Guideline / public regulatory information】
FDA — expanded access (compassionate use) information for patients
Index verified: Aug 16, 2026
USFDA【Guideline / public regulatory information】
FDA — oncology (cancer) / hematologic malignancies approval notifications
Index verified: Aug 16, 2026
USFDA【Guideline / public regulatory information】
FDA — ongoing accelerated approvals for oncology indications
Index verified: Aug 16, 2026
USNCCN【Guideline / public regulatory information】
NCCN Guidelines — palliative care category listing
Index verified: Aug 16, 2026
USNCCN【Guideline / public regulatory information】
NCCN Guidelines — public index by cancer type (free registration)
Index verified: Aug 16, 2026
USNCCN【Guideline / public regulatory information】
NCCN Guidelines for Patients — plain-language versions
Index verified: Aug 16, 2026
CNNMPA【Guideline / public regulatory information】
NMPA 药品 — national drug approval announcements
Index verified: Aug 16, 2026
CNCDE【Guideline / public regulatory information】
药物临床试验登记与信息公示平台 — national registry of drug trials conducted in China
Index verified: Aug 16, 2026